Ascendiant Capital Rates Synergy CHC (SNYR) buy

Ascendiant Capital maintains its buy rating on Synergy CHC Corp. with a $3.75 target, a 1813.27% upside from the current price.

By EarningsIQ Research Desk · Published Jun 14, 2026, 2:01 AM EDT · Updated Jun 15, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Ascendiant Capital rated Synergy CHC Corp. ($SNYR) "buy" with a $3.75 price target on June 10, 2026.

SNYR Synergy CHC Corp.

$0.01 -88.89% since first close

All Daily close · Sep 28, 2026

Key Points

Ascendiant Capital reiterated its buy rating on Synergy CHC Corp. (SNYR) with a price target of $3.75 as of June 10, 2026.
Ascendiant Capital's $3.75 price target implies 1813.27% upside from Synergy CHC Corp.'s ($SNYR) current $0.20 share price.
Shares of Synergy CHC Corp. traded at $0.20, with a market cap of about $2.92 million and a 52-week high of $4.00.
The company operates in the healthcare sector, offering consumer products like supplements and wellness items, and is based in Windham, Maine.

Get $SNYR trade alerts by text

We text you when insiders, Congress or big funds trade $SNYR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Synergy CHC Corp. alert may contain errors. Disclosures

Ascendiant Capital has reiterated its buy rating on Synergy CHC Corp. (NasdaqCM: SNYR), maintaining its price target at $3.75 as of June 10, 2026. This affirmation suggests continued confidence in the company's potential despite current market challenges.

Synergy CHC Corp. Stock Up 116.6%

Shares of SNYR are currently trading near $0.20, with a market capitalization of approximately $2.92 million. The company has a forward P/E ratio of about 1.31 and a beta of 0.511, indicating relatively low volatility compared to the market. The stock has seen a 52-week low of $0.18 and a high of $4.00. Its 50-day moving average stands at $0.37, while the 200-day moving average is at $1.55. The company has a current ratio of 0.926 and a quick ratio of 0.228, highlighting some liquidity challenges.

12-month forecast

$SNYR price target

Synergy CHC Corp. daily closes and this analyst's $3.75 target. Not advice.

Recent Earnings

Synergy CHC Corp. reported revenue of about $27.7 million, though it experienced a revenue decline of 32.8%. The company has a net margin of -56.98%, reflecting ongoing financial difficulties. Its earnings per share (EPS) is negative at -1.6, indicating the company is not currently profitable. The next earnings report is expected on August 13, 2026.

Analysts Set New Price Targets

On June 10, 2026, Ascendiant Capital maintained its buy rating on Synergy CHC Corp. with a price target of $3.75. Previously, on April 14, 2026, the firm had set a higher target of $5.5, and earlier this year, on February 2, 2026, they initiated coverage with a $5.0 target. Another firm, Roth Capital, maintained a buy rating with a $7.0 target on November 14, 2025, while Roth MKM had initiated coverage with a $10.0 target back in January 2025. The consensus recommendation remains a strong buy, with a mean target price of $3.75 based on one analyst opinion.

About Synergy CHC Corp.

Synergy CHC Corp., headquartered in Windham, Maine, operates in the healthcare sector, specifically in medical distribution. The company provides a variety of consumer health care, beauty, and lifestyle products across the United States, Canada, Mexico, and internationally. Its product lineup includes brain health supplements under the FOCUSfactor brand, lifestyle products under the Flat Tummy brand, hand care under the Hand MD brand, and more. Led by CEO Jack Ross, Synergy CHC Corp. employs 28 people.

Bottom Line

Ascendiant Capital's maintained buy rating on Synergy CHC Corp. reflects ongoing optimism about the company's future prospects, despite its current financial hurdles. Investors closely monitor these ratings as they provide insights into potential long-term value. The reiterated buy rating, along with the $3.75 price target, suggests that analysts see potential for growth, but it's important to remember that these filings are backward-looking and may not represent the current market sentiment.